VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.

Authors

Jesse M Damsker
Laurie S ConklinFollow
Soheil Sadri
Blythe C Dillingham, George Washington University
Karuna Panchapakesan
Christopher R Heier, George Washington UniversityFollow
John M McCall
Anthony D Sandler, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

9-1-2016

Journal

Inflammation Research

Volume

65

Issue

9

Inclusive Pages

737-743

DOI

10.1007/s00011-016-0956-8

Keywords

Animals; Anti-Inflammatory Agents; Body Size; Cells, Cultured; Colitis; Cytokines; Disease Models, Animal; Epithelial Cells; Female; Humans; Male; Mice, Inbred BALB C; NF-kappa B; Pregnadienediols; Trinitrobenzenesulfonic Acid

APA Citation

Damsker, J., Conklin, L., Sadri, S., Dillingham, B., Panchapakesan, K., Heier, C., McCall, J., & Sandler, A. (2016). VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.. Inflammation Research, 65 (9). http://dx.doi.org/10.1007/s00011-016-0956-8

Peer Reviewed

1